Discounted Cash Flow (DCF) Analysis Levered
Syndax Pharmaceuticals, Inc. (SNDX)
$16.57
-0.07 (-0.45%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 1.52 | 1.52 | 1.52 | 139.71 | 12,866.58 | 1,184,955.36 | 109,129,155.41 | 10,050,313,232.65 | 925,589,460,413.05 | 85,242,701,336,375.50 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -68.53 | -50.61 | -71.26 | 29.13 | -133.68 | -29,698,472.66 | -2,735,098,165.16 | -251,890,461,149.57 | -23,197,998,969,946.03 | -2,136,433,248,617,798 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.19 | -0.19 | -0.19 | -17.22 | -1,586.06 | -146,068.99 | -13,452,308.43 | -1,238,898,192.57 | -114,097,051,805.23 | -10,507,834,549,081.48 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -68.72 | -50.80 | -71.45 | 11.91 | -1,719.73 | -29,844,541.64 | -2,748,550,473.59 | -253,129,359,342.14 | -23,312,096,021,751.25 | -2,146,941,083,166,879.50 |
Weighted Average Cost Of Capital
| Share price | $ 16.57 |
|---|---|
| Beta | 1.037 |
| Diluted Shares Outstanding | 60.76 |
| Cost of Debt | |
| Tax Rate | 3.74 |
| After-tax Cost of Debt | 260.09% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 9.051 |
| Total Debt | 1.16 |
| Total Equity | 1,006.81 |
| Total Capital | 1,007.97 |
| Debt Weighting | 0.12 |
| Equity Weighting | 99.88 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 1.52 | 1.52 | 1.52 | 139.71 | 12,866.58 | 1,184,955.36 | 109,129,155.41 | 10,050,313,232.65 | 925,589,460,413.05 | 85,242,701,336,375.50 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -68.53 | -50.61 | -71.26 | 29.13 | -133.68 | -29,698,472.66 | -2,735,098,165.16 | -251,890,461,149.57 | -23,197,998,969,946.03 | -2,136,433,248,617,798 |
| Capital Expenditure | -0.19 | -0.19 | -0.19 | -17.22 | -1,586.06 | -146,068.99 | -13,452,308.43 | -1,238,898,192.57 | -114,097,051,805.23 | -10,507,834,549,081.48 |
| Free Cash Flow | -68.72 | -50.80 | -71.45 | 11.91 | -1,719.73 | -29,844,541.64 | -2,748,550,473.59 | -253,129,359,342.14 | -23,312,096,021,751.25 | -2,146,941,083,166,879.50 |
| WACC | ||||||||||
| PV LFCF | -1,719.73 | -27,295,172.53 | -2,299,034,971.41 | -193,644,564,593.41 | -16,310,416,267,178.58 | -1,373,804,007,188,181 | ||||
| SUM PV LFCF | -1,390,310,394,350,097 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 9.34 |
| Free cash flow (t + 1) | -2,189,879,904,830,217.25 |
| Terminal Value | -29,834,876,087,605,140 |
| Present Value of Terminal Value | -19,091,009,364,195,432 |
Intrinsic Value
| Enterprise Value | -20,481,319,758,545,528 |
|---|---|
| Net Debt | -73.19 |
| Equity Value | -20,481,319,758,545,456 |
| Shares Outstanding | 60.76 |
| Equity Value Per Share | -337,080,552,395,737.13 |